Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Interleukin 17 and Its Involvement in Renal Cell Carcinoma

Version 1 : Received: 19 June 2022 / Approved: 21 June 2022 / Online: 21 June 2022 (05:11:36 CEST)

How to cite: Jarocki, M.; Karska, J.; Kowalski, S.; Kiełb, P.; Nowak, Ł.; Krajewski, W.; Saczko, J.; Kulbacka, J.; Szydełko, T.; Małkiewicz, B. Interleukin 17 and Its Involvement in Renal Cell Carcinoma. Preprints 2022, 2022060286 (doi: 10.20944/preprints202206.0286.v1). Jarocki, M.; Karska, J.; Kowalski, S.; Kiełb, P.; Nowak, Ł.; Krajewski, W.; Saczko, J.; Kulbacka, J.; Szydełko, T.; Małkiewicz, B. Interleukin 17 and Its Involvement in Renal Cell Carcinoma. Preprints 2022, 2022060286 (doi: 10.20944/preprints202206.0286.v1).

Abstract

Nowadays molecular and immunological research is essential for the better understanding of tumor cells pathophysiology. The increasing number of neoplasms is taken under ‘the molecular magnifying glass’ therefore it is possible to discover complex relationships between cytophysiology and immune system action. An example could be renal cell carcinoma (RCC) which has deep interactions with immune mediators such as Interleukin 17 (IL-17) - an inflammatory cytokine reacting to tissue damage and external pathogens. RCC is one of the most fatal urological cancer because of its often late diagnosis and poor susceptibility to therapies. IL-17 and its relation with tumors is extremely complex and constitute a recent topic for numerous research. What is worth highlighting is IL-17 dual character in cancer development - it could be pro- as well as antitumorigenic. The aim of this review is to summarize the newest data considering multiple connections between IL-17 and RCC.

Keywords

interleukin-17; renal cell carcinoma; immunotherapy; inflammation; tumor microenviroment; tumor development; Th17 lymphocytes

Subject

MEDICINE & PHARMACOLOGY, Urology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.